Keyphrases
In Cancer
100%
Zirconium-89 (89Zr)
100%
Clinical Response
100%
Non-invasive Approach
100%
PD-1 Blockade
100%
Pembrolizumab
100%
Non-small Cell Lung Cancer (NSCLC)
36%
Anti-PD-1 Antibody
36%
Positron Emission Tomography
27%
Antibody Treatment
27%
Tumor
18%
Inflammation
18%
Melanoma Cells
18%
Tumor Response
18%
Tumor Uptake
18%
SUVmax
18%
Melanoma
9%
Standard of Care
9%
Overall Survival
9%
Lymph Node
9%
Spleen
9%
Biodistribution
9%
Treatment Response
9%
Lymphoid Tissue
9%
Programmed Death-ligand 1 (PD-L1)
9%
Geometric Mean
9%
Optimal Dose
9%
Patient Survival
9%
Patient's Will
9%
Imaging Studies
9%
Standardized Uptake Value
9%
Metastatic Melanoma
9%
Advanced Melanoma
9%
Tumor-like Lesions
9%
Waldeyer's Ring
9%
Organ Uptake
9%
Advanced or Metastatic
9%
Optimal Time Point
9%
Progression-free
9%
Response Evaluation Criteria in Solid Tumors (RECIST)
9%
Medicine and Dentistry
Malignant Neoplasm
100%
Zirconium 89
100%
Pembrolizumab
100%
Neoplasm
63%
Non Small Cell Lung Cancer
36%
Positron Emission Tomography
27%
Nodular Melanoma
27%
Treatment Response
9%
Biodistribution
9%
Lymphatic Tissue
9%
Overall Survival
9%
Metastatic Melanoma
9%
Optimal Drug Dose
9%
Lymph Node
9%
Progression Free Survival
9%
Standardized Uptake Value
9%
Waldeyer Ring
9%
Programmed Death 1 Receptor
9%